Full Text | PDF

J Cancer 2016; 7(11):1441-1451. doi:10.7150/jca.15556 This issue Cite

Review

Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice

Anliang Dong¹, Yan Lu¹, Bingjian Lu^2✉

1. Women's Hospital & Institute of Translational Medicine, School of Medicine, Zhejiang University, China;
2. Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, China.

✉ Corresponding author: Bingjian Lu, M.D., Department of Surgical Pathology, the Affiliated Women's Hospital, School of Medicine, Zhejiang University, 1 Xueshi Road, Hangzhou, Zhejiang Province, PR China, 310006. Email: lbjedu.cn. Tel: 86-571-89991702. More

Abstract

Ovarian carcinoma is the most lethal gynecological malignancy worldwide. Recent advance in genomic/epigenomic researches will impact on our prevention, detection and intervention on ovarian carcinoma. Detection of germline mutations in BRCA1/BRCA2, mismatch repair genes, and other genes in the homologous recombination/DNA repair pathway propelled the genetic surveillance of most hereditary ovarian carcinomas. Germline or somatic mutations in SMARCA4 in familial and sporadic small cell carcinoma of the ovary, hypercalcemia type, lead to our recognition on this rare aggressive tumor as a new entity of the atypical teratoma/rhaboid tumor family. Genome-wide association studies have identified many genetic variants that will contribute to the evaluation of ovarian carcinoma risk and prognostic prediction. Whole exome sequencing and whole genome sequencing discovered rare mutations in other drive mutations except p53, but demonstrated the presence of high genomic heterogeneity and adaptability in the genetic evolution of high grade ovarian serous carcinomas that occurs in cancer progression and chemotherapy. Gene mutations, copy number aberrations and DNA methylations provided promising biomarkers for the detection, diagnosis, prognosis, therapy response and targets of ovarian cancer. These findings underscore the necessity to translate these potential biomarkers into clinical practice.

Keywords: ovarian carcinoma, mutation, hereditary, whole genome sequencing, whole exome sequencing, methylation.

Citation styles

©2024 Ivyspring International Publisher. Terms of use